Clinical Trial Update: Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia [Phase 4]

View source ↗

Summary

Phase 4 trial reporting that orlistat reduces uric acid in overweight/obese patients with hyperuricemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia
• Obesity

Drugs mentioned

• Orlistat (orlistat)

Snippet

Sponsor: Shanghai 10th People's Hospital | Conditions: Uric Acid | Phase 4 | Status: COMPLETED